(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are NASDAQ TEST STOCK, Liquid Media Group Ltd., and Inovio Pharmaceuticals.

The three biggest losers today are VerifyMe, Infosys Limited, and WiMi Hologram Cloud.

Winners today

1. NASDAQ TEST STOCK (ZVZZT) – 42.67%

NASDAQ ended the session with NASDAQ TEST STOCK jumping 42.67% to $14.98 on Thursday, after five sequential sessions in a row of losses. NASDAQ rose 1.99% to $12,166.27, after three consecutive sessions in a row of losses, on what was an all-around up trend exchanging session today.

Yearly Top and Bottom Value

NASDAQ TEST STOCK’s stock is valued at $14.98 at 17:32 EST, way under its 52-week high of $16.78 and way higher than its 52-week low of $10.00.

More news about NASDAQ TEST STOCK.

2. Liquid Media Group Ltd. (YVR) – 28.86%

Liquid Media Group Ltd. operates as a media and entertainment company. The company provides video game products primarily for the casual-game consumers; and publishes video games for interactive entertainment hardware platforms. It also offers gaming, visual effects (VFX), and production services; and distributes third-party film and TV content through its digital platforms. Liquid Media Group Ltd. is headquartered in Vancouver, Canada.

NASDAQ ended the session with Liquid Media Group Ltd. jumping 28.86% to $0.19 on Thursday while NASDAQ jumped 1.99% to $12,166.27.

Earnings Per Share

As for profitability, Liquid Media Group Ltd. has a trailing twelve months EPS of $-1.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -121.98%.

Yearly Top and Bottom Value

Liquid Media Group Ltd.’s stock is valued at $0.19 at 17:32 EST, way below its 52-week high of $0.74 and way above its 52-week low of $0.13.

Revenue Growth

Year-on-year quarterly revenue growth grew by 28490.7%, now sitting on 4.52M for the twelve trailing months.

Moving Average

Liquid Media Group Ltd.’s worth is way under its 50-day moving average of $0.22 and way below its 200-day moving average of $0.30.

Volume

Today’s last reported volume for Liquid Media Group Ltd. is 10345400 which is 591.81% above its average volume of 1495410.

More news about Liquid Media Group Ltd..

3. Inovio Pharmaceuticals (INO) – 22.91%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals jumping 22.91% to $0.90 on Thursday while NASDAQ rose 1.99% to $12,166.27.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.27%.

Sales Growth

Inovio Pharmaceuticals’s sales growth is negative 59.5% for the present quarter and 0.5% for the next.

Moving Average

Inovio Pharmaceuticals’s worth is way below its 50-day moving average of $1.45 and way below its 200-day moving average of $1.83.

More news about Inovio Pharmaceuticals.

4. Xenetic Biosciences (XBIOW) – 21.67%

NASDAQ ended the session with Xenetic Biosciences jumping 21.67% to $0.73 on Thursday while NASDAQ jumped 1.99% to $12,166.27.

Volume

Today’s last reported volume for Xenetic Biosciences is 9 which is 91% below its average volume of 100.

More news about Xenetic Biosciences.

5. X4 Pharmaceuticals (XFOR) – 19.99%

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with X4 Pharmaceuticals jumping 19.99% to $1.14 on Thursday, after three sequential sessions in a row of gains. NASDAQ jumped 1.99% to $12,166.27, after three consecutive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, X4 Pharmaceuticals has a trailing twelve months EPS of $-1.51.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -135.58%.

More news about X4 Pharmaceuticals.

6. Marathon (MARA) – 14.72%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets in United States. As of December 31, 2021, it had approximately 8,115 bitcoins, which included the 4,794 bitcoins held in the investment fund. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Marathon jumping 14.72% to $11.41 on Thursday while NASDAQ jumped 1.99% to $12,166.27.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-6.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.77%.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was 7.88%, 2.49%, and 7.01%.

Marathon’s highest amplitude of average volatility was 9.76% (last week), 6.46% (last month), and 7.01% (last quarter).

Previous days news about Marathon

• Marathon petroleum (mpc) stock moves 0.72%: what you should know. According to Zacks on Tuesday, 11 April, "Any recent changes to analyst estimates for Marathon Petroleum should also be noted by investors. ", "Valuation is also important, so investors should note that Marathon Petroleum has a Forward P/E ratio of 6.47 right now. "
• Marathon oil (mro) stock moves 1.36%: what you should know. According to Zacks on Tuesday, 11 April, "Any recent changes to analyst estimates for Marathon Oil should also be noted by investors. ", "In the latest trading session, Marathon Oil (MRO Quick QuoteMRO – Free Report) closed at $26.11, marking a +1.36% move from the previous day. "

More news about Marathon.

7. StoneCo (STNE) – 10.23%

StoneCo Ltd. provides financial technology solutions to merchants and integrated partners to conduct electronic commerce across in-store, online, and mobile channels in Brazil. It distributes its solutions, principally through proprietary Stone Hubs, which offer hyper-local sales and services; and technology and solutions to digital merchants through sales and technical personnel and software vendors, as well as sells solutions to brick-and-mortar and digital merchants through sales team. As of December 31, 2021, the company served approximately 1,766,100 clients primarily small-and-medium-sized businesses; and marketplaces, e-commerce platforms, and integrated software vendors. StoneCo Ltd. was founded in 2000 and is headquartered in George Town, the Cayman Islands.

NASDAQ ended the session with StoneCo rising 10.23% to $11.59 on Thursday, after four sequential sessions in a row of gains. NASDAQ rose 1.99% to $12,166.27, after three successive sessions in a row of losses, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, StoneCo has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.31%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 300% and 50%, respectively.

More news about StoneCo.

8. Zai Lab (ZLAB) – 10.06%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab rising 10.06% to $39.40 on Thursday, following the last session’s downward trend. NASDAQ jumped 1.99% to $12,166.27, after three consecutive sessions in a row of losses, on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-4.96.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.05%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 22.8% and positive 48.8% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 33.5%, now sitting on 196.61M for the twelve trailing months.

More news about Zai Lab.

9. XP (XP) – 9.29%

XP Inc. provides financial products and services in Brazil. It offers securities brokerage, private pension plans, commercial, and investment banking products, such as loan operations and transactions in the foreign exchange markets and deposits; product structuring and capital markets services for corporate clients and issuers of fixed income products; advisory services for mass-affluent and institutional clients; and wealth management services for high-net-worth customers and institutional clients. The company also offers Xpeed, an online financial education portal that offers seminars, classes, and learning tools to help teach individuals on topics, such as basics of investing, techniques, and investment strategies, as well as insurance brokerage services. In addition, it operates XP Platform, an open product platform that provides clients to access investment products in the market, including equity and fixed income securities, mutual and hedge funds, private equity, structured products, credit cards, loan operations, life insurance, pension plans, real-estate investment funds, and others. The company was founded in 2001 and is based in São Paulo, Brazil.

NASDAQ ended the session with XP rising 9.29% to $14.12 on Thursday while NASDAQ jumped 1.99% to $12,166.27.

Earnings Per Share

As for profitability, XP has a trailing twelve months EPS of $1.19.

PE Ratio

XP has a trailing twelve months price to earnings ratio of 11.87. Meaning, the purchaser of the share is investing $11.87 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.52%.

Previous days news about XP

• XP inc. (xp) moves 12.4% higher: will this strength last?. According to Zacks on Wednesday, 12 April, "For XP Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. ", "So, make sure to keep an eye on XP going forward to see if this recent jump can turn into more strength down the road."

More news about XP.

10. Riot Blockchain (RIOT) – 9.23%

Riot Platforms, Inc., together with its subsidiaries, focuses on bitcoin mining operations in North America. It operates through Bitcoin Mining, Data Center Hosting, and Electrical Products and Engineering segments. As of December 31, 2021, it operated approximately 30,907 miners. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is headquartered in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain jumping 9.23% to $13.49 on Thursday while NASDAQ rose 1.99% to $12,166.27.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-3.64.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.07%.

More news about Riot Blockchain.

Losers Today

1. VerifyMe (VRMEW) – -15.56%

NASDAQ ended the session with VerifyMe sliding 15.56% to $0.15 on Thursday, after five consecutive sessions in a row of losses. NASDAQ jumped 1.99% to $12,166.27, after three sequential sessions in a row of losses, on what was an all-around up trend trading session today.

More news about VerifyMe.

2. Infosys Limited (INFY) – -10.05%

Infosys Limited, together with its subsidiaries, provides consulting, technology, outsourcing, and next-generation digital services in North America, Europe, India, and internationally. It provides application development and management, independent validation, product engineering and management, infrastructure management, enterprise application management, and support and integration services. The company's products and platforms include Finacle, a core banking solution; Edge suite of products; Infosys Nia, an artificial intelligence platform; Infosys McCamish – an insurance platform; Wingspan, a customizable learning platform; Stater mortgage servicing platform; Panaya automation suite; and Skava, an e-commerce suite. The company serves clients in the financial services and insurance, life sciences and healthcare, manufacturing, retail, consumer packaged goods and logistics, hi-tech, communications, telecom OEM, media, energy, utilities, resources, services, and other industries. It has collaboration agreements with Rolls-Royce, BP plc, Newmont Corporation, RXR Realty, Majesco Limited, and Centre for Accessibility Australia; and a strategic partnership with The Economist Group Limited to enable and enhance sustainability solutions through a business-to-business model. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Limited in June 2011. Infosys Limited was incorporated in 1981 and is headquartered in Bengaluru, India.

NYSE ended the session with Infosys Limited sliding 10.05% to $15.35 on Thursday while NYSE jumped 0.84% to $15,630.89.

Earnings Per Share

As for profitability, Infosys Limited has a trailing twelve months EPS of $0.71.

PE Ratio

Infosys Limited has a trailing twelve months price to earnings ratio of 21.63. Meaning, the purchaser of the share is investing $21.63 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.49%.

Volume

Today’s last reported volume for Infosys Limited is 27286300 which is 236.04% above its average volume of 8119940.

More news about Infosys Limited.

3. WiMi Hologram Cloud (WIMI) – -6.78%

WiMi Hologram Cloud Inc. provides augmented reality (AR) based holographic services and products in China. It operates in two segments, Augmented Reality, and AR Entertainment. The company primarily offers holographic AR advertising services and holographic AR entertainment products. Its holographic AR advertising software enables users to insert into video footages real or animated three dimensional objects; and online holographic AR advertising solution embeds holographic AR ads into films. The company's holographic AR entertainment products consist primarily of payment middleware software, game distribution platform, and holographic mixed reality software. WiMi Hologram Cloud Inc. was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with WiMi Hologram Cloud falling 6.78% to $1.10 on Thursday while NASDAQ jumped 1.99% to $12,166.27.

Earnings Per Share

As for profitability, WiMi Hologram Cloud has a trailing twelve months EPS of $-0.52.

Revenue Growth

Year-on-year quarterly revenue growth declined by 15.9%, now sitting on 851.86M for the twelve trailing months.

Yearly Top and Bottom Value

WiMi Hologram Cloud’s stock is valued at $1.10 at 17:32 EST, way below its 52-week high of $2.53 and way higher than its 52-week low of $0.56.

Moving Average

WiMi Hologram Cloud’s value is way under its 50-day moving average of $1.23 and way below its 200-day moving average of $1.36.

Volume

Today’s last reported volume for WiMi Hologram Cloud is 363117 which is 51.85% below its average volume of 754255.

More news about WiMi Hologram Cloud.

4. Abercrombie & Fitch Company (ANF) – -6.67%

Abercrombie & Fitch Co., through its subsidiaries, operates as a specialty retailer. The company operates in two segments, Hollister and Abercrombie. It offers an assortment of apparel, personal care products, intimates, and accessories for men, women, and children under the Hollister, Abercrombie & Fitch, abercrombie kids, Moose, Seagull, and Gilly Hicks brands. As of May 28, 2020, it operated approximately 850 stores in North America, Europe, Asia, and the Middle East. The company sells products through its stores and direct-to-consumer channels; various third-party wholesale, franchise, and licensing arrangements; and e-commerce platforms. Abercrombie & Fitch Co. was founded in 1892 and is headquartered in New Albany, Ohio.

NYSE ended the session with Abercrombie & Fitch Company dropping 6.67% to $25.60 on Thursday while NYSE jumped 0.84% to $15,630.89.

Earnings Per Share

As for profitability, Abercrombie & Fitch Company has a trailing twelve months EPS of $0.05.

PE Ratio

Abercrombie & Fitch Company has a trailing twelve months price to earnings ratio of 512. Meaning, the purchaser of the share is investing $512 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.35%.

Sales Growth

Abercrombie & Fitch Company’s sales growth is negative 0.3% for the current quarter and 1.1% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Abercrombie & Fitch Company’s EBITDA is 0.56.

Volume

Today’s last reported volume for Abercrombie & Fitch Company is 1512890 which is 2.21% below its average volume of 1547090.

Moving Average

Abercrombie & Fitch Company’s value is below its 50-day moving average of $28.03 and way higher than its 200-day moving average of $21.66.

More news about Abercrombie & Fitch Company.

5. Progressive Corporation (PGR) – -6.51%

The Progressive Corporation, an insurance holding company, provides personal and commercial auto, personal residential and commercial property, general liability, and other specialty property-casualty insurance products and related services in the United States. It operates in three segments: Personal Lines, Commercial Lines, and Property. The Personal Lines segment writes insurance for personal autos and recreational vehicles (RV). This segment's products include personal auto insurance; and special lines products, including insurance for motorcycles, ATVs, RVs, watercrafts, snowmobiles, and related products. The Commercial Lines segment provides auto-related primary liability and physical damage insurance, and business-related general liability and property insurance for autos, vans, pick-up trucks, and dump trucks used by small businesses; tractors, trailers, and straight trucks primarily used by regional general freight and expeditor-type businesses, and long-haul operators; dump trucks, log trucks, and garbage trucks used by dirt, sand and gravel, logging, and coal-type businesses; and tow trucks and wreckers used in towing services and gas/service station businesses; as well as non-fleet and airport taxis, and black-car services. The Property segment writes residential property insurance for homeowners, other property owners, and renters, as well as offers personal umbrella insurance, and primary and excess flood insurance. The company also offers policy issuance and claims adjusting services; and acts as an agent to homeowner general liability, workers' compensation insurance, and other products. In addition, it provides reinsurance services. The company sells its products through independent insurance agencies, as well as directly on Internet through mobile devices, and over the phone. The Progressive Corporation was founded in 1937 and is headquartered in Mayfield, Ohio.

NYSE ended the session with Progressive Corporation falling 6.51% to $138.51 on Thursday, after three successive sessions in a row of losses. NYSE jumped 0.84% to $15,630.89, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Progressive Corporation has a trailing twelve months EPS of $1.19.

PE Ratio

Progressive Corporation has a trailing twelve months price to earnings ratio of 116.39. Meaning, the purchaser of the share is investing $116.39 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.23%.

Yearly Top and Bottom Value

Progressive Corporation’s stock is valued at $138.51 at 17:32 EST, below its 52-week high of $146.50 and way above its 52-week low of $106.35.

More news about Progressive Corporation.

6. American Eagle Outfitters (AEO) – -6.42%

American Eagle Outfitters, Inc. operates as a specialty retailer that provides clothing, accessories, and personal care products under the American Eagle and Aerie brands. The company provides jeans, and specialty apparel and accessories for men and women; and intimates, activewear, and swim collections, as well as personal care products for women. In addition, it offers sports apparel under the Tailgate brand; and menswear products under the Todd Snyder New York brand name. As of February 1, 2020, it operated approximately 940 American Eagle stores, 148 Aerie stand-alone stores, 5 Tailgate stores, and two Todd Snyder stores in the United States, Canada, Mexico, China, and Hong Kong. It also ships to 81 countries through its Websites; and offers its merchandise at 217 locations operated by licensees in 24 countries, as well as provides products through its Websites ae.com, aerie.com, and ToddSnyder.com. American Eagle Outfitters, Inc. was founded in 1977 and is headquartered in Pittsburgh, Pennsylvania.

NYSE ended the session with American Eagle Outfitters sliding 6.42% to $13.41 on Thursday, following the last session’s downward trend. NYSE rose 0.84% to $15,630.89, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, American Eagle Outfitters has a trailing twelve months EPS of $0.64.

PE Ratio

American Eagle Outfitters has a trailing twelve months price to earnings ratio of 20.95. Meaning, the purchaser of the share is investing $20.95 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.28%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 4.99B for the twelve trailing months.

Volume

Today’s last reported volume for American Eagle Outfitters is 5192590 which is 39.78% above its average volume of 3714720.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Apr 4, 2023, the estimated forward annual dividend rate is 0.4 and the estimated forward annual dividend yield is 2.98%.

More news about American Eagle Outfitters.

7. Beyond Air (XAIR) – -5.34%

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.

NASDAQ ended the session with Beyond Air falling 5.34% to $6.20 on Thursday while NASDAQ jumped 1.99% to $12,166.27.

Earnings Per Share

As for profitability, Beyond Air has a trailing twelve months EPS of $-1.91.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -80.58%.

More news about Beyond Air.

8. Gyrodyne (GYRO) – -4.61%

Gyrodyne, LLC. owns, leases and manages diverse commercial properties. The firm is distinguished by its service-oriented philosophy toward property ownership and management. Gyrodyne has grown from a largely Long Island player during the past into a diversified East Coast presence with an emphasis on medical office product.

NASDAQ ended the session with Gyrodyne falling 4.61% to $9.25 on Thursday while NASDAQ rose 1.99% to $12,166.27.

Earnings Per Share

As for profitability, Gyrodyne has a trailing twelve months EPS of $0.17.

PE Ratio

Gyrodyne has a trailing twelve months price to earnings ratio of 54.41. Meaning, the purchaser of the share is investing $54.41 for every dollar of annual earnings.

Yearly Top and Bottom Value

Gyrodyne’s stock is valued at $9.25 at 17:32 EST, way below its 52-week high of $13.42 and way higher than its 52-week low of $7.80.

Moving Average

Gyrodyne’s value is above its 50-day moving average of $8.47 and below its 200-day moving average of $9.75.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Gyrodyne’s stock is considered to be overbought (>=80).

More news about Gyrodyne.

9. Exicure (XCUR) – -4.5%

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA–based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.

NASDAQ ended the session with Exicure sliding 4.5% to $1.06 on Thursday while NASDAQ jumped 1.99% to $12,166.27.

Earnings Per Share

As for profitability, Exicure has a trailing twelve months EPS of $-0.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.74%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 928%, now sitting on 28.83M for the twelve trailing months.

More news about Exicure.

10. Xcel Brands (XELB) – -4.42%

Xcel Brands, Inc., together with its subsidiaries, operates as a media and consumer products company in the United States. The company designs, produces, licenses, markets, and sells branded apparel, footwear, accessories, jewelry, home goods, and other consumer products; and acquires consumer lifestyle brands, including the Isaac Mizrahi, the Judith Ripka, the H Halston, the Halston Heritage, and the C Wonder brands. It licenses its brands to third parties; and provides design, production, and marketing services for promotion and distribution through a ubiquitous-channel retail sales strategy, including distribution through interactive television, the Internet, and traditional brick-and-mortar retail channels. The company also offers social media marketing and other marketing, and public relations support for its brands. In addition, it markets the Mizrahi brands through isaacmizrahi.com; the Halston Brand through halston.com; the Judith Ripka Fine Jewelry brand through judithripka.com; and the C Wonder brands through cwonder.com. Xcel Brands, Inc. is headquartered in New York, New York.

NASDAQ ended the session with Xcel Brands dropping 4.42% to $0.58 on Thursday while NASDAQ rose 1.99% to $12,166.27.

Earnings Per Share

As for profitability, Xcel Brands has a trailing twelve months EPS of $-0.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.83%.

Moving Average

Xcel Brands’s worth is way below its 50-day moving average of $0.75 and way under its 200-day moving average of $0.93.

Revenue Growth

Year-on-year quarterly revenue growth declined by 60%, now sitting on 29.81M for the twelve trailing months.

Volume

Today’s last reported volume for Xcel Brands is 9053 which is 9.06% below its average volume of 9955.

More news about Xcel Brands.

Stay up to date with our winners and losers daily report